137764-59-1

Upstream product

• 501-53-1 benzyl chloroformate 
• 123715-02-6 H-Dmt 

Downstream Products

• 736992-21-5 D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide 
• 137650-60-3 α(S)-amino-N-<1(S)-<(1,1-dimethylethoxy)methyl>-2-(3-phenylpropoxy)ethyl>-4-hydroxy-2,6-dimethylbenzenepropanamide 
• 137650-36-3 α-amino-4-hydroxy-2,6-dimethyl-N-<1(R)-methyl-2-oxo-6-phenylhexyl>benzenepropanamide hydrochloride 

Relevant academic research and scientific papers

PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES

The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2.

Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide

A number of analogues of the recently disclosed analgesic dipeptide 2,6- dimethyl-L-tyrosyl-D-alanine-phenylpropylamide (SC-39566, 2) were prepared. These analogues contained oxymethylene, aminomethylene, ketomethylene, bismethylene, and trans double bond (including vinyl fluoride) isosteric replacements for the amide bond between the D-alanine and phenylpropylamine units in 2. These compounds were tested in opioid binding assays and in the mouse writhing assay for analgesic activity. Though not as potent as 2, the oxymethylene, and trans double bond isosteres showed analgesic activity. The aminomethylene analogues also showed binding activity in subnanomolar concentrations at the μ receptor. The amide bond between 2,6-dimethyl-L- tyrosine and D-alanine units seems to be critical for opioid activity.